Sab biotherapeutics appoints jay skyler, md, to the board of directors

Miami, may 06, 2024 (globe newswire) -- sab biotherapeutics (nasdaq: sabs) (the “company” or “sab”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced that jay skyler, md, macp, frcp has been appointed to the company's board of directors.
SABS Ratings Summary
SABS Quant Ranking